Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with...

Area of Science:

• Cardiology
• Gastroenterology
• Pharmacology

Background:

• Patients undergoing percutaneous coronary intervention (PCI) with dual antiplatelet therapy (DAPT) are at risk for upper gastrointestinal bleeding (UGIB).
• The role of proton pump inhibitors (PPIs) in managing UGIB in this high-risk population requires evaluation regarding cardiovascular safety and inflammatory effects.

Purpose of the Study:

• To evaluate the impact of PPIs on cardiovascular events (CVEs) in patients with UGIB receiving DAPT post-PCI.
• To assess the effect of PPIs on key inflammatory factors in patients with UGIB undergoing DAPT.

Main Methods:

• Retrospective analysis of 166 patients with UGIB on DAPT after PCI.
• Patients were divided into two groups: those receiving PPIs and those not (non-PPI group).
• Comparison of CVE incidence and serum levels of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) between groups.

Main Results:

• Melena was the most common clinical presentation of UGIB.
• No significant difference in CVE incidence was observed between the PPI and non-PPI groups.
• PPI use was associated with significantly lower levels of CRP and TNF-α compared to the non-PPI group (P < 0.05).

Conclusions:

• PPIs are safe concerning CVEs in UGIB patients on DAPT after PCI.
• PPIs demonstrate an anti-inflammatory effect by reducing CRP and TNF-α levels in this patient cohort.
• Melena is a frequent manifestation of UGIB in patients on DAPT post-PCI.